REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2023

Apr 24, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2023-04-21

Reporting Person: BROWN MICHAEL S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-21	Common Stock	M	3070	$520.01	Acquired	4317	Direct
2023-04-21	Common Stock	S	3070	$798.42	Disposed	1247	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-21	Non-Qualified Stock Option (right to buy)	$520.01	M	3070	Disposed	2026-01-04	Common Stock (3070)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5000	Indirect
Common Stock	6162	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 22, 2023.

F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.